Carmichael Hill & Associates’s Adaptimmune Therapeutics ADAP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $499 | Hold |
525
| – | – | ﹤0.01% | 641 |
|
|
2024
Q2 | $512 | Hold |
525
| – | – | ﹤0.01% | 647 |
|
|
2024
Q1 | $830 | Hold |
525
| – | – | ﹤0.01% | 633 |
|
|
2023
Q4 | $417 | Hold |
525
| – | – | ﹤0.01% | 656 |
|
|
2023
Q3 | $410 | Hold |
525
| – | – | ﹤0.01% | 654 |
|
|
2023
Q2 | $486 | Hold |
525
| – | – | ﹤0.01% | 655 |
|
|
2023
Q1 | $573 | Hold |
525
| – | – | ﹤0.01% | 649 |
|
|
2022
Q4 | $766 | Hold |
525
| – | – | ﹤0.01% | 621 |
|
|
2022
Q3 | $1K | Hold |
525
| – | – | ﹤0.01% | 643 |
|
|
2022
Q2 | $1K | Hold |
525
| – | – | ﹤0.01% | 629 |
|
|
2022
Q1 | $1K | Buy |
525
+175
| +50% | +$333 | ﹤0.01% | 643 |
|
|
2021
Q4 | $1K | Buy |
350
+140
| +67% | +$400 | ﹤0.01% | 644 |
|
|
2021
Q3 | $1K | Hold |
210
| – | – | ﹤0.01% | 645 |
|
|
2021
Q2 | $1K | Buy |
210
+90
| +75% | +$429 | ﹤0.01% | 635 |
|
|
2021
Q1 | $1K | Hold |
120
| – | – | ﹤0.01% | 621 |
|
|
2020
Q4 | $1K | Buy |
120
+80
| +200% | +$667 | ﹤0.01% | 603 |
|
|
2020
Q3 | $0 | Buy |
+40
| New | – | ﹤0.01% | 620 |
|